Herpes zoster vaccine: A health economic evaluation for Switzerland

Herpes zoster vaccine: A health economic evaluation for Switzerland

Herpes zoster (HZ) or “shingles” results from a reactivation of the varicella zoster virus (VZV) acquired during primary infection (chickenpox) and surviving in the dorsal root ganglia. In about 20% of cases, a complication occurs, known as post-herpetic neuralgia (PHN). A live attenuated vaccine ag...

Full description

Bibliographic Details
Main Authors: Patricia R. Blank, Zanfina Ademi, Xiaoyan Lu, Thomas D. Szucs, Matthias Schwenkglenks
Format: Article
Language:English
Published: Taylor & Francis Group 2017-07-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
cost-effectiveness
herpes zoster
post-herpetic neuralgia
switzerland
vaccination
Online Access:http://dx.doi.org/10.1080/21645515.2017.1308987

Internet

http://dx.doi.org/10.1080/21645515.2017.1308987

Similar Items